Evidence map›Paper›PMID 39281596›Full record

ArticleHeliyon2024

Development and validation of a risk prognostic model based on the

Jing Zhou, Li Guo, Yuzhen Wang, Lina Li, Yahuan Guo, Lian Duan, Mi Jiao, Pan Xi, Pei Wang

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing ZhouDepartment of Oncology, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.
Li GuoDepartment of Geriatrics, South District, 986th Hospital of the People's Liberation Army Air Force, Xi'an, 710054, China.
Yuzhen WangDepartment of Oncology, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.
Lina LiDepartment of Oncology, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.
Yahuan GuoDepartment of Oncology, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.
Lian DuanDepartment of Oncology, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.
Mi JiaoDepartment of Oncology, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.
Pan XiDepartment of Radiotherapy, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.
Pei WangDepartment of Anesthesiology, Shaanxi Province Tumor Hospital, Xi'an, 710061, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Stomach adenocarcinoma (STAD) is one of the most common malignancies. Infection of helicobacter pylori ( Methods: The single-cell RNA sequencing (scRNA-seq) dataset and the clinic information and RNA-seq datasets of STAD patients were collected for establishing a prognostic model and for validation. The "Seurat" and "harmony" packages were used to process the scRNA-seq data. Key gene modules were sectioned using the "limma" package and the "WGCNA" package. Kaplan-Meier (KM) and Receiver Operating Characteristic Curve (ROC) analyses were performed with "survminer" package. The "GSVA" package was employed for single sample gene set enrichment analysis (ssGSEA). Cell migration and invasion were measured by carrying out wound healing and trans-well assays. Results: A total of 17397 were screened and classified into 8 cell type clusters, among which the macrophage cluster was closely associated with the Conclusion: The gene expression profile served as an indicator of the survival for patients with STAD and addressed the clinical significance of using

Indexed as

H. pylori infection phenotypeRiskScoreSingle cell RNA-Seq profilessGSEAStomach adenocarcinoma (STAD)WGCNA

Identifiers

PMID39281596
PMCPMC11401198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.